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Abstract
Secondary antibody deficiency can occur as a result of haematological malignancies or certain medications, but not much is
known about the clinical and immunological features of this group of patients as a whole. Here we describe a cohort of 167
patients with primary or secondary antibody deficiencies on immunoglobulin (Ig)-replacement treatment. The
demographics, causes of immunodeficiency, diagnostic delay, clinical and laboratory features, and infection frequency
were analysed retrospectively. Chemotherapy for B cell lymphoma and the use of Rituximab, corticosteroids or
immunosuppressive medications were the most common causes of secondary antibody deficiency in this cohort. There was
no difference in diagnostic delay or bronchiectasis between primary and secondary antibody deficiency patients, and both
groups experienced disorders associated with immune dysregulation. Secondary antibody deficiency patients had similar
baseline levels of serum IgG, but higher IgM and IgA, and a higher frequency of switched memory B cells than primary
antibody deficiency patients. Serious and non-serious infections before and after Ig-replacement were also compared in
both groups. Although secondary antibody deficiency patients had more serious infections before initiation of Ig-
replacement, treatment resulted in a significant reduction of serious and non-serious infections in both primary and
secondary antibody deficiency patients. Patients with secondary antibody deficiency experience similar delays in diagnosis
as primary antibody deficiency patients and can also benefit from immunoglobulin-replacement treatment.
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Introduction
Antibody deficiencies are defined by a loss of immunoglobulins
or failure of immunoglobulin function, resulting in increased
susceptibility to infection. In primary deficiencies inherited or
sporadic genetic mutation(s), in some cases with unknown
environmental cofactors, are suspected with no other known
cause [1,2]. Secondary antibody deficiency as a consequence of
other diseases or medications can also occur [3–5]. Studies
describe secondary antibody deficiencies as a result of haemato-
logical malignancy [6,7], immunosuppressive [8–10] or anti-
convulsant medications [11], protein-losing enteropathy [12],
nephrotic syndrome and trauma [13]. Antibody deficiencies are
associated with infections, immune dysfunction, end organ
damage and significant morbidity and mortality [14,15]. Immu-
noglobulin (Ig)-replacement for primary antibody deficiency is
known to reduce infections, morbidity and mortality [16–18]. A
small number of studies have demonstrated that (Ig)-replacement
therapy is also effective in reducing severe infections in those with
secondary antibody deficiency as a result of a haematological
malignancy [19–22]. However as a whole, secondary antibody
deficiencies are poorly described in the literature and clinical
management guidance is usually extrapolated from experience
with primary antibody deficiencies.
Although primary immunodeficiencies are rare, the advent of
international registries has enabled more data to be pooled to
further advance the understanding of clinical characteristics and
treatment [23,24]. By comparison, little has been published as yet
about the overall prevalence of secondary antibody deficiencies,
whether there is a delay in diagnosis and what the outcomes of Ig-
replacement treatment are. The natural history of this heteroge-
neous group is not well understood, nor are we able to reliably
identify who and when to treat. Since much information already
published is on primary deficiencies, it may also be helpful to put
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secondary antibody deficiencies into context, relative to primary
immunodeficiencies.
This study aimed to describe and compare features of primary
and secondary antibody deficiency patients. We describe the
characteristics of the cohort in terms of diagnosis, delay in
diagnosis, bronchiectasis, possible causes of secondary immuno-
deficiency, concomitant disorders and immunological parameters.
Serious and non-serious infection outcomes after Ig-replacement
treatment are also compared in primary and secondary antibody
deficiency patients.
Patients and Methods
Ethics Statement
All data was collected after obtaining written informed consent
and in accordance with approval by the City and East London
Research Ethics Committee.
Study population and data collection
Adult subjects receiving Ig-replacement treatment in May 2013
seen in the immunodeficiency clinic at Barts Health NHS Trust
were included in the study. Diagnoses were made by use of
standard criteria where appropriate [25,26]. The diagnosis of
common variable immune deficiency (CVID) was made according
to the criteria of decreased serum IgG, IgA and/or IgM, poor
antibody response to vaccination and the exclusion of other causes
of deficiency [27]. An ‘inflammatory’ CVID diagnosis was made
based on a combination of clinical features, including persistent
lymphadenopathy, (hepato)splenomegaly, synovitis, CT features of
nodules or pulmonary infiltrates, cytopaenias, abnormal liver
function in the absence of infection or other cause, or evidence of
inflammatory infiltrates or granulomata on biopsy, in the absence
of infectious or other causes. ‘Probable CVID’ subjects were those
that fulfilled most CVID criteria but secondary causes could not be
definitively excluded. Subjects with hypogammaglobulinaemia
were defined as having serum IgG of ,5.5 g/L, the lower limit of
normal for our local laboratory, with or without low IgA or IgM.
Specific antibody deficiency was defined by poor or absent
antibody response after polysaccharide pneumococcal (Pneumo-
vax-23) vaccination. Poor response was defined as achieving
antibody levels of ,0.35 mg/l, conferring basic protection against
infection, to fewer than 8 of 13 serotypes; a more rigorous
definition of antibody deficiency than that recommended by the
American Academy of Allergy and Clinical Immunology [28].
Subclass deficiency subjects had low levels of one or more IgG
subclasses in the context of normal total immunoglobulin isotypes
[26], and were commenced on Ig-replacement treatment if
symptomatic despite prophylactic antibiotics. Agammaglobulinae-
mia was characterised by panhypogammaglobulinaemia and
infection onset ,5 years of age – 11 subjects had X-linked
agammaglobulinaemia (XLA) with a BTK mutation and one had
autosomal recessive agammaglobulinaemia. The other primary
immunodeficiencies were defined by genetic testing and/or clinical
symptoms according to standard criteria [25]. The complete
patient information dataset is available as the ‘Supplementary
Dataset’ File.
Categorisation into ‘Primary’ or ‘Secondary’ antibody deficien-
cy groups was based largely on patients fulfilling positive diagnostic
criteria (e.g. CVID, XLA) for the primary group. For diagnosis of
secondary antibody deficiency, clinical judgement took into
account the timing of potential causes of deficiency (e.g.
chemotherapy) and the development of symptoms or abnormal
immunoglobulin levels. The ‘probable’ primary and secondary
groups included those in whom a primary or secondary deficiency
was suspected based on clinical history, but where other causes
could not be excluded or where definitive information about
timing of symptoms was not available (for example, more
frequent/serious infections following immunosuppressive medica-
tion, suggesting a secondary deficiency). Demographic and
diagnostic data were obtained retrospectively by reviewing
medical records.
Diagnostic delay was defined as the time between patient-
reported symptom onset or first documented serious infection, and
antibody deficiency diagnosis. Subjects for whom dates of
symptoms or diagnosis were unclear were excluded from this
analysis. Serum IgG, IgA and IgM levels were recorded and the
frequency of switched memory B cells (CD19+CD27+IgM2IgD2)
determined as a percentage of total B cells using standard methods
[29]. Analysis of serum immunoglobulin levels excluded those
patients with specific/subclass deficiencies and was available for 58
primary group subjects and 27 secondary group subjects prior to
Ig-replacement. Mean trough IgG levels over the year 2012/2013
were calculated - for patients starting Ig-replacement in the year
2012/2013, only IgG levels after the first 5 infusions were included
to eliminate a loading effect.
Immunoglobulin-replacement therapy
Patients were treated initially with a dose of 0.1 g/kg/week as
recommended [26,30] with dose adjustment to minimise infection
frequency on an individual patient basis [16].
Infection outcomes
For infection outcomes, data was collected for the year
preceding initiation of Ig-replacement and for the year 01/06/
12 to 31/05/13. For those where post-treatment infection data of
,1 year was available (22 subjects), the number of infections were
normalised on a pro-rata basis. Infections that overlapped with
diagnosis and initiation of Ig-replacement were only included in
the pre-treatment count. Infection data was available for a
minimum of 53/126 primary and 28/39 secondary subjects pre-
treatment, and for 115/126 primary and 37/39 secondary subjects
post-treatment. ‘Serious infections’ were defined as infections
requiring hospitalisation and/or intravenous antibiotics. ‘Non-
serious’ infections included any mild or moderate infection, with
or without antibiotic treatment. The number and type of non-
serious infections were largely patient-reported with microbiolog-
ical confirmation when appropriate and serious infection data was
collected from medical records. For all historical pre-treatment
data, infection counts were taken from clinical notes.
Statistical methods
Data between primary and secondary groups were analysed by
a two-tailed unpaired t-test with Welch’s correction (unequal
variance t-test). A two-tailed paired t-test was used for analysis of
infection frequency pre- and post-treatment. Where comparisons
were made between diagnostic sub-groups the Kruskal-Wallis test
was used. Data on the number of switched memory B cells and
bronchiectasis was only available for a small number of patients
and was analysed using the Mann-Whitney test. P values of ,0.05
were considered significant; all data analysis was carried out using
GraphPad Prism 5.0.
Results
Immunodeficiency cohort
A total of 167 patients receiving Ig-replacement were identified
(98 women and 69 men) including 113 with primary immunode-
ficiencies, 13 with a probable primary deficiency, 26 with
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secondary immunodeficiencies, 13 with a probable secondary
immunodeficiency and 2 that could not be definitively classified.
The subjects with secondary or probable secondary deficiencies
were older (median age 64.5 yrs and 58 yrs) than the primary
groups (45 yrs and 52 yrs). The most common diagnosis in the
primary group was CVID accounting for 69.9% of the group (of
which 20.3% had inflammatory CVID), and 10.6% of the primary
group had agammaglobulinemia. A diagnosis of hypogammaglob-
ulinemia was more common in the secondary and probable
secondary groups (80.8% and 69.2%) and a smaller proportion
had a specific or subclass defect (Table 1). The ‘definite’ and
‘probable’ groups had similar proportions of subjects with each
type of diagnosis (Figure S1), thus for much of the further analysis
the groups were combined and compared as primary (n = 126) and
secondary (n = 39) groups.
Characteristics of secondary antibody deficiency
Based on the clinical history and/or timing of drug treatments
relative to onset of symptoms, the most likely cause of secondary
antibody deficiency in each subject was identified (Table 2). The
most common likely cause was previous cancer chemotherapy for
B cell lymphoma (11 subjects), of which most regimens included
Rituximab (RTX). Four of these subjects had additionally
undergone allogeneic stem cell transplantation. Although antibody
deficiency can occur either as a result of the malignancy itself or
secondary to treatment of the malignancy, based on the timing of
symptoms, the antibody deficiency only manifested after chemo-
therapy in these B cell lymphoma patients. Immunosuppressive
therapy for autoimmune or rheumatic diseases (5 subjects) and
high dose or frequent corticosteroids for asthma or COPD (6
subjects) were also common likely causes. Three subjects had
untreated B- or plasma cell clonal proliferations, and one had
chronic hepatitis C. In the probable secondary deficiency group,
the most common likely causes were corticosteroid, immunosup-
pressive or anti-convulsant medication use. No patient had protein
loss such as nephrotic syndrome or protein-losing enteropathy as
the cause of their severe antibody deficiency.
The type of medications used before antibody deficiency
diagnosis and the time between first use and diagnosis are shown
for the secondary group (Table 3) and for individual patients that
had received immunosuppressive medications (Table S1 in Tables
S1). The most common medication used was corticosteroids
(including that given as part of a chemotherapy regimen), followed
by chemotherapy and RTX. The time between first use and
diagnosis was shortest for immunosuppressive medications (medi-
an 0.5 yrs), followed by chemotherapy (2 yrs), Rituximab (3.5 yrs)
and corticosteroids (5 yrs). For those that received more than one
treatment of RTX (e.g. for recurrent lymphoma, or autoimmune
disease) or more than one immunosuppressive medication before
diagnosis, there was a longer time from first use to symptoms
(3.5 yrs vs. 5 yrs for Rituximab and 0.5 yrs vs. 1.3 yrs for
immunosuppressive drugs). This is likely due to the antibody
deficiency only developing or becoming symptomatic after the
second or subsequent treatment, suggesting a cumulative effect.
Note that the timing between medication use and diagnosis was
difficult to determine for most of the probable secondary group
due to unclear clinical history data (this was usually the reason for
classification as ‘probable’).
Table 1. Immunodeficiency cohort on Ig-replacement treatment.
PRIMARY
PROBABLE
PRIMARY SECONDARY
PROBABLE
SECONDARY UNKNOWN
TOTAL 113 13 26 13 2
Median age (range) 45 (17–91) 52 (30–81) 64.5 (40–82) 58 (28–79) 75.5 (74–77)
Male 47 5 10 5 1
Female 66 8 16 8 1
CVID 79 (69.9%) 79 (69.9%) - - -
Non-inflammatory CVID 63 - - - -
Inflammatory CVID 16 - - - -
Probable CVID - 8 - - -
HYPOGAMMAGLOBULINAEMIA 5 (4.4%) 3 (23.1%) 21 (80.8%) 9 (69.2%) 2 (100%)
SPECIFIC OR SUBCLASS DEFICIENCY 10 (8.9%) 2 (15.4%) 4 (15.4%) 4 (30.8%) -
AGAMMAGLOBULINAEMIA 12 (10.6%) - - - -
XLA 11 - - - -
Autosomal agammaglobulinaemia 1 - - - -
OTHER 7 (6.2%) - 1 (3.8%) - -
Combined deficiency 1 - 1 - -
Good syndrome 1 - - - -
ALPS 1 - - - -
Ataxia telangiectasia 1 - - - -
HyperIgE syndrome 1 - - - -
WHIM syndrome 2 - - - -
CVID indicates common variable immune deficiency; ALPS, autoimmune lymphoproliferative syndrome; and WHIM, warts hypogammaglobulinaemia infections and
myelokathexis syndrome.
doi:10.1371/journal.pone.0100324.t001
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Diagnosis of antibody deficiency
Delay in diagnosis of antibody deficiencies has been associated
with greater infection-related morbidity [31,32]. We assessed the
diagnosis delay, defined as the number of years between symptom
onset and diagnosis of antibody deficiency. There was no
significant difference in diagnosis delay between the primary
(median 2.5 yrs) and secondary (1 yr) groups (Figure 1A). In the
primary group, the diagnosis of specific or subclass deficiencies was
more delayed (median 11 yrs) than either CVID (2 yrs) or
hypogammaglobulinemia (1 yr), although the number of subjects
analysed was limited (Figure S2A). Similarly in the secondary
group, diagnosis of antibody deficiency due to corticosteroid use
(median 2 yrs) may be delayed in comparison to the chemotherapy
(0.5 yrs) or malignancy (0.5 yrs) groups (Figure S2B).
Bronchiectasis is a complication of lung infections and has been
shown to be associated with delay in diagnosis of antibody
deficiency in some CVID cohorts [14], although not in others
[15]. Bronchiectasis was identified in 37.3% of the primary group
Table 2. Likely cause of secondary antibody deficiency in each subject.
SECONDARY PROBABLE SECONDARY
UNTREATED MALIGNANCY 3 -
CLL 1 -
MM 1 -
MGUS 1 -
CHEMOTHERAPY 11 1
with RTX 9 1
with stem cell transplant 4 -
CORTICOSTEROIDS FOR ASTHMA OR COPD 6 5
AUTOIMMUNE OR RHEUMATIC 5 3
RA or SLE 2 2
Wegener’s granulomatosis 1 -
RA/SLE with RTX 1 1
SLE/Sjogren’s with RTX 1 -
OTHER 1 4
Hepatitis C infection 1 -
Previous anti-convulsant drugs - 3
Previous immunosuppressive drugs - 1
CLL indicates chronic lymphocytic leukaemia; MM, multiple myeloma; MGUS, monoclonal gammopathy of unknown significance; RTX, Rituximab; RA, rheumatoid
arthritis; and SLE, systemic lupus erythematosus.
doi:10.1371/journal.pone.0100324.t002
Table 3. Number of immunosuppressive therapies used by each group before symptom onset.
SECONDARY PROBABLE SECONDARY
Number
Median years between first
use and symptoms (range) Number
CORTICOSTEROIDS 18 5 (1–19) 10
CHEMOTHERAPY 11 2 (1–15) 1
RITUXIMAB 11 3.5 (0.5–10) 2
More than one RTX treatment (including maintenance therapy) 6 5 (1.5–10) 1
AT LEAST ONE OTHER IMMUNOSUPPRESSIVE DRUG 8 0.5 (0.5–5) 4
More than one other immunosuppressive drug 6 1.3 (0.5–4) 3
Mycophenolate mofetil 3 - 2
Methotrexate 3 - 1
Cyclosporine 3 - 1
Cyclophosphamide 2 - 0
Hydroxychloroquinine 2 - 2
Leflunomide 1 - 1
ANTI-CONVULSANTS - - 3
Number indicates the number of therapies used (a single subject may have had more than one therapy).
doi:10.1371/journal.pone.0100324.t003
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and 28.2% of the secondary group (Figure 1B). In the primary
group bronchiectasis was most prevalent in the ‘Other immuno-
deficiencies’ and agammaglobulinaemia subjects and in ,30% of
CVID subjects (Figure S3A). In the secondary group half of the
autoimmune/rheumatic sub-group and a third of the chemother-
apy sub-group had bronchiectasis (Figure S3B). Despite this
surprisingly high frequency of subjects with bronchiectasis, there
was no significant difference in diagnostic delay between subjects
with bronchiectasis and those without, for either primary or
secondary antibody deficiency groups (Figure 1C).
Autoimmune disorders, suggesting immune dysregulation, were
present in both primary and secondary immunodeficiency subjects
(Table S2 in Tables S1), despite differences in the causes of
antibody deficiency. The secondary group had a higher frequency
of lymphoma in our cohort, although the incidence of Non-
Hodgkins lymphoma is also known to be increased in older CVID
patients [33]. In the primary group autoimmune disorders or
lymphoma were likely to be manifestations of the primary
deficiency whereas in the secondary group, antibody deficiency
was a consequence of therapy for these disorders. Interestingly,
there was a similarly high frequency of non-bronchiectatic chronic
lung disease (asthma and/or COPD) in both groups (23.9%
primary and 34.1% secondary), which may have implications for
susceptibility to respiratory infections.
Immunological parameters before Ig-replacement
Mean serum immunoglobulin levels were calculated for the year
preceding initiation of Ig-replacement (excluding specific or
subclass deficiency subjects). There was no significant difference
in the pre-treatment IgG level between primary and secondary
groups (median 2.79 g/L vs. 3.30 g/L) (Figure 2A). However,
serum IgA (median 0.17 g/L vs. 0.60 g/L) and IgM (median
0.26 g/L vs. 0.47 g/L) levels were significantly higher in the
secondary group (Figure 2B–C). Low frequencies of switched
memory B cells (CD19+CD27+IgM2IgD2) have been associated
with inflammatory/granulomatous and splenomegaly CVID
clinical phenotypes [34], but the status of this B cell subset in
those with secondary antibody deficiencies is unknown. Only one
subject analysed in the secondary group had low numbers of
switched memory B cells (,2%) and as a group, secondary
antibody deficiency patients had significantly higher frequencies
(median 6.9%) than the primary group (2.5%) (Figure 2D). The
majority of patients previously treated with RTX had recovered
normal circulating B cell numbers by the time of starting Ig-
replacement, with the exception of one subject, and the two
subjects on RTX maintenance treatment. Overall, those with
secondary deficiency have similarly low IgG levels, although not as
a result of low switched memory B cell frequencies.
Infection outcomes after Ig-replacement treatment
The number of infections in subjects was compared before Ig-
replacement (in the year preceding treatment) and after treatment
(in the year 2012/2013). In this cohort, the primary group had
been on Ig-replacement for a significantly longer time than the
secondary group (median 3 yrs vs. 1 yr). The majority of subjects
were on home therapy and a large proportion on sub-cutaneous
administration (Table 4). Although the dose of IgG given (g/kg/4-
weeks) was higher in the primary group, median trough IgG levels
in the year 2012/2013 were similar for the primary (median
10.30 g/L) and secondary groups (9.75 g/L).
Figure 1. Diagnostic delay and the presence of bronchiectasis. Diagnostic delay (time between symptom onset and antibody deficiency
diagnosis) was determined for the primary (n = 58) and secondary (n = 25) groups (A). The percentage of subjects with or without bronchiectasis
(determined by high-resolution CT scan) is shown for each group (B). Diagnostic delay by bronchiectasis presence or absence is shown for the
primary (n = 45) and secondary (n = 21) groups (C). The bars in panels A and C represent median values. Data in panel A were analysed by a two-tailed
unequal variance t-test and data in panel C were analysed by a two-tailed Mann-Whitney test; n.s. non-significant (p values ,0.05 were considered
significant).
doi:10.1371/journal.pone.0100324.g001
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Figure 2. Immunological parameters before Ig-replacement treatment. Serum IgG (A), IgA (B) and IgM (C) levels in the year before Ig-
replacement are shown for the primary (n = 58) and secondary groups (n = 27). Each symbol represents the mean value over the year for one subject
and the bars represent the group median. The frequency of switched memory B cells (CD19+CD27+IgD2IgM2) as a proportion of peripheral blood B
cells is shown for the primary (n = 50) and secondary (n = 10) groups (D). Dotted lines indicate the normal reference ranges for each. Data in panels A–
C were analysed by a two-tailed unequal variance t-test and data in panel D were analysed by a two-tailed Mann-Whitney test; * p,0.05, ** p,0.01;
n.s. non-significant.
doi:10.1371/journal.pone.0100324.g002
Table 4. Ig-replacement therapy in primary and secondary antibody deficiency patients.
PRIMARY SECONDARY p value
NUMBER OF SUBJECTS ON PROPHYLACTIC ANTIBIOTICS
Before starting Ig-replacement 47 (37.3%) 27 (69.2%)
After starting Ig-replacement 64 (50.8%) 23 (60.0%)
MEDIAN IgG DOSE, g/week (RANGE) 11.20 (3.2–32.0) 10.10 (3.2–30.0) n.s. (0.4645)
(mean 6 95% C.I.) (12.2060.92) (11.7061.64)
MEDIAN IgG DOSE, g/kg (RANGE) 0.30 (0.10–1.30) 0.20 (0.10–2.00) n.s. (0.1808)
(mean 6 95% C.I.) (0.4160.91) (0.3660.22)
MEDIAN IgG DOSE, g/kg/4-weeks (RANGE) 0.70 (0.35–2.03) 0.53 (0.35–1.03) * 0.0110
(mean 6 95% C.I.) (0.8060.12) (0.5960.10)
MEDIAN TROUGH IgG, g/L (RANGE) 10.30 (5.46–18.93) 9.75 (6.35–13.70) n.s. (0.1705)
(mean 6 95% C.I.) (10.6260.50) (9.9260.63)
MEDIAN NUMBER OF YEARS ON Ig-REPLACEMENT
(RANGE)
3 (,1–28) 1 (,1–9) * 0.0184
(mean 6 95% C.I.) (3.7760.87) (2.5460.74)
ROUTE OF ADMINISTRATION
IV 60 (47.6%) 13 (33.3%)
SC 66 (52.4%) 26 (66.6%)
PLACE OF ADMINISTRATION
Home 80 (63.5%) 25 (64.1%)
Barts Health 26 (20.6%) 9 (23.1%)
Other local hospital 20 (15.9%) 5 (12.8%)
Data were analysed with a two-tailed Mann-Whitney test; n.s., non-significant. IV indicates intravenous; and SC, sub-cutaneous.
doi:10.1371/journal.pone.0100324.t004
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In the year before Ig-replacement, the secondary group had a
significantly higher frequency of serious infections requiring
hospitalisation and/or IV antibiotics, and a greater proportion
of subjects with more than one serious infection compared to the
primary group (Figure 3A). There was no significant difference in
serious infections between secondary sub-groups such as chemo-
therapy vs. immunosuppressive (data not shown), suggesting that
infection susceptibility was not related to the type of underlying
disease. The number of non-serious infections (any patient-
reported infections) before Ig-replacement did not differ between
the primary and secondary groups (Figure 3B). The number of
days on antibiotics before Ig-replacement also did not differ
between the groups (data not shown). After Ig-replacement
treatment, there was no significant difference in the number of
serious infections between the primary and secondary immuno-
deficiency groups, but the number of non-serious infections was
significantly lower in the secondary group (Figure 3C–D).
Comparing infections in individual subjects before and after Ig-
replacement, there was a significant decrease in serious and non-
serious infections in both the primary and secondary groups
(Figure 3E–F). The types of infections experienced are shown in
Table S3 in Tables S1 - the most common serious infection before
treatment was pneumonia and the most common non-serious
infections were respiratory infections. The primary group tended
to have more skin, sinus and ear infections than the secondary
group. After treatment, there were an increased proportion of
subjects that were infection-free in both the primary and
secondary groups. The secondary group had a greater proportion
of infection-free subjects than the primary group (23.1% vs.
16.6%) after Ig-replacement treatment.
The majority of secondary antibody deficiency patients received
a trial of antibiotic prophylaxis as standard before Ig-replacement
treatment [35]. There was a small increase in the proportion of
subjects on antibiotic prophylaxis after Ig-replacement in the
primary group and a small decrease in the secondary group
(Table 4). Non-serious infections were more frequent in those on
prophylactic antibiotics in the primary group before and after Ig-
replacement (Figure S4A–B) which is probably due to antibiotic
prophylaxis being used more often in those experiencing frequent
infections.
Discussion
We show that for our cohort, whatever the underlying cause of
antibody deficiency, infection frequency is reduced by Ig-
replacement. Secondary antibody deficiency patients respond at
least as well, and possibly better, to antibody replacement, as
evidenced by the similar reduction in serious infection frequency,
greater reduction in non-serious infection frequency and lower
immunoglobulin dose required by the secondary antibody
deficiency group.
Registry studies have identified a smaller proportion (,1%) of
antibody deficiency subjects with a secondary cause [36] than in
our cohort. This could reflect exclusion of secondary antibody
deficiencies from these registries, that patients with secondary
antibody deficiency are more likely to be managed by specialists
other than immunologists, or lack of recognition of the significance
of secondary antibody deficiency. Most of the secondary antibody
deficiency group (,75%) had hypogammaglobulinaemia with a
smaller proportion having a specific or subclass defect. In our
cohort, the most common likely causes of secondary immunode-
ficiency were previous chemotherapy or immunosuppressive
therapy, corticosteroids for chronic lung disease and less
commonly haematological malignancies. Patients such as immu-
nosuppressed solid organ transplant recipients who are also at risk
of having secondary antibody deficiency [37] were not seen at our
centre, neither were patients with low antibodies secondary to
protein loss. This could reflect referral bias, but could equally
reflect the increased susceptibility to infection of those with defects
in immunoglobulin production and especially in those with the
combination of B cell (pre)malignancy and immunosuppressive
therapies, particularly therapies that target B cells.
In the secondary group, a delay of several years was noted
between initial immunosuppressive therapy and the onset of
infections. This delay was different for each drug type which may
be due to the frequency, potency and regimens of the drugs used.
Hypogammaglobulinaemia has previously been noted in RTX-
treated patients after a delay of 1–2 years [38]. The longest delay
was observed for corticosteroid use which may reflect intermittent
use over a long period of time. Additionally, we observed a
potentially longer time to symptom development after repeated
treatments with one agent (e.g. RTX) or several agents (different
immunosuppressive drugs). This may be indicative of a cumulative
and combinatorial dose effect, which has been previously reported
for repeated RTX cycles [39] and for cyclophosphamide followed
by RTX [40]. However, studies of larger populations are needed
to confirm this observation.
Since this study only includes those that are symptomatic and
have been started on Ig-replacement, it is not clear what
proportion of all those on such immunosuppressive drugs develop
hypogammaglobulinaemia and how many become symptomatic.
Estimates vary, with studies describing the incidence of hypogam-
maglobulinaemia as 14–35% following RTX treatment [9,39–43],
27–54% for those with chronic lymphocytic leukaemia [6,7], 17%
of asthmatics on corticosteroids [44] and 40–63% of solid organ
transplant recipients [45]. However not all with hypogammaglob-
ulinaemia develop overt infections severe enough to require Ig-
replacement, and those with low anti-pneumococcal antibodies
may be particularly susceptible [7].
Despite the differences in causes of antibody deficiencies
between the primary and secondary groups, they had a similar
frequency of disorders related to immune dysregulation (infections,
autoimmunity, malignancy) and for chronic lung disease. This
overlap has led to diagnostic uncertainty which we have reflected
in our patients classified as ‘probable’; the similar characteristics of
the ‘probable’ and ‘definite’ groups in terms of diagnosis type,
immune parameters and infection outcomes (data not shown), lead
us to believe that the classification is reliable.
There was a surprisingly high incidence of bronchiectasis in our
cohort (,34%) compared to 11.2% in another study [46].
However, the ESID registry-based study found a Europe-wide
incidence of 23%, which was noted to be higher in British cohorts
[36]. Interestingly, up to half of those with secondary deficiency
caused by chemotherapy or immunosuppressive drugs also had
bronchiectasis. Although this was not associated with a diagnostic
delay or poorer infection outcomes in our cohort (data not shown),
bronchiectasis has been associated with reduced survival [15],
implying that monitoring of end organ complications is important
for secondary deficiency patients too. The higher incidence of
bronchiectasis (and other complications) could explain the
relatively high immunoglobulin dose and trough levels for our
cohort [24]. Although data was limited, there did not appear to be
any overall difference in diagnostic delay between the primary and
secondary groups in our cohort. Greater diagnostic delay may
occur for those on intermittent corticosteroids: recurrent respira-
tory infections might erroneously be attributed to chronic lung
disease rather than underlying immune deficiency.
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The primary antibody deficient patients, of whom the majority
had CVID or XLA, had lower baseline levels of serum IgM and
IgA and fewer switched memory B cells than the secondary
patients before Ig-replacement therapy. Sub-groups of CVID
patients have been identified based on the number of total,
switched memory and transitional B cells [47,48]. Low frequencies
of switched memory B cells in particular have been associated with
splenomegaly and granulomatous/inflammatory CVID [34].
Differences in B cell subset numbers could yield clues as to the
mechanism of antibody deficiency. Low total B cell numbers may
be a result of a defect in early B cell differentiation and low
switched memory B cells may reflect a germinal centre defect
Figure 3. Number of serious and non-serious infections before and after Ig-replacement treatment. The number of serious infections
requiring hospitalisation or IV antibiotics and the number of patient-reported non-serious infections in the year preceding Ig-replacement treatment
(A–B) and in the year 2012/2013 (C–D) is shown. The bars represent the group medians. Serious (E) and non-serious infections (F) are shown for each
patient before (filled symbols) and after (open symbols) treatment. Data in panels A–D were analysed by a two-tailed unequal variance t-test and data
in panels E–F were analysed by a two-tailed paired t-test; * p,0.05, ** p,0.01, *** p,0.001; n.s. non-significant.
doi:10.1371/journal.pone.0100324.g003
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[34,49]. The molecular mechanisms of secondary antibody
deficiencies are virtually unknown and are likely to be heteroge-
neous depending on the cause of deficiency. The normal number
of switched memory B cells observed in our cohort of secondary
antibody patients may suggest a post-germinal centre (GC) defect
in antibody production, such as a defect in plasmablast differen-
tiation or poor survival and/or replenishment of the plasma cell
pool. Patients with low levels of immunoglobulins before RTX or
immunosuppressive treatments are more likely to develop hypo-
gammaglobulinaemia [9,37], suggesting that some people may
have a pre-existing predisposition to antibody deficiency. Treat-
ment with RTX targets CD20+ B cells, including the pro-B-cell to
mature GC phenotypes, plasma cells are unaffected, and follicular
dendritic and T-helper cell numbers in tissue may also be reduced
[50]. Future work to study this compartment in detail prior to
RTX may help identify the at-risk phenotype.
In the year preceding Ig-replacement, the secondary group had
a greater number of serious infections and several patients had
more than one. Since there did not appear to be any diagnostic
delay between the primary and secondary groups, secondary
deficiency patients may be relatively asymptomatic until they
develop a serious infection that warrants referral to an immunol-
ogist. The greater occurrence of serious infections may also be
explained by the older age and co-morbidities, including drug and
disease-associated immune defects of the secondary group. An
alternative explanation is that only those secondary antibody
deficient patients with severe enough symptoms to be on Ig-
replacement were included, whereas Ig-replacement is initiated as
first-line treatment for most confirmed primary antibody deficien-
cy patients. The rate of decline of immunoglobulin levels in some
secondary immunodeficiency patients may also have a bearing on
the rate of emergence of infectious complications.
After Ig-replacement, infections were significantly reduced in
both groups thus the cause of antibody deficiency may not be
important in itself. Ig-replacement has been previously shown to
be effective in reducing infections in haematological malignancy
patients with hypogammaglobulinaemia [19,20,22] but has not
previously been studied in patients selected according to antibody
deficiency rather than underlying cause. Trough IgG levels were
similar in both groups and did not correlate with infections (data
not shown) due to our practice of increasing dosage if too many
breakthrough infections occur [16]. Additionally, in our cohort the
primary group had been on Ig-replacement for a longer time than
the secondary group (3 yrs vs. 1 yr) which may mean that their
trough IgG levels had already been optimised to minimise
breakthrough infections, making the lower post-treatment infec-
tion rate in the secondary group even more noteworthy. The dose
of IgG used, which appears to be effective, was lower in the
secondary group despite similar pre-treatment levels, suggesting
reduced peripheral consumption or that replacement itself may
have a greater effect on endogenous Ig production.
This study is the first to describe a cohort of unselected
secondary antibody deficiency compared to primary antibody
deficiency patients and to compare outcomes on Ig-replacement
therapy. Secondary antibody deficiency manifesting as hypogam-
maglobulinaemia or specific/subclass deficiencies can occur with
haematological malignancies or after cell depletion therapy,
chemotherapy, immunosuppressive or corticosteroid medications.
Despite having a greater number of serious infections in the year
before Ig-replacement therapy, secondary antibody deficiency
patients had significantly fewer non-serious infections than the
primary group after therapy. Therefore, regardless of whether the
cause of symptomatic antibody deficiency is primary or secondary,
both groups benefit from Ig-replacement therapy.
Supporting Information
Figure S1 Primary and secondary antibody deficiency
diagnoses. The number of subjects with each diagnosis classified
as having a primary, probable primary, secondary, probable
secondary or unknown antibody deficiency is shown.
(TIF)
Figure S2 Diagnostic delay by primary and secondary
antibody deficiency sub-groups. Diagnostic delay (time
between symptom onset and antibody deficiency diagnosis) was
analysed by diagnosis for the primary group (A) and by likely cause
of deficiency for the secondary group (B). Data were analysed by
the Kruskal-Wallis test, p values of ,0.05 were considered
significant; n.s. non-significant.
(TIF)
Figure S3 Bronchiectasis by primary and secondary
antibody deficiency sub-groups. The percentage of each sub-
group with or without bronchiectasis (determined by high-
resolution CT scan) is shown by diagnosis for the primary group
(A) and by likely cause of deficiency for the secondary group (B).
(TIF)
Figure S4 Prophylactic antibiotics and the occurrence
of non-serious infections. The number of non-serious
infections in those receiving antibiotic prophylaxis compared to
those not on prophylactic antibiotics before (A) and after (B) Ig-
replacement is shown. Data were analysed by a two-tailed unequal
variance t-test; * p,0.05.
(TIF)
Tables S1 Contains the following files: Table S1. Immunosup-
pressive therapies used by individual patients before diagnosis.
Table S2. Disorders in primary and secondary antibody deficiency
patients. Table S3. Number and type of infections experienced by
the primary and secondary group before and after Ig-replacement.
(DOCX)
Dataset S1 A file of the full dataset is provided.
(XLS)
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